|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007113,
umls-concept:C0013216,
umls-concept:C0016360,
umls-concept:C0205179,
umls-concept:C0205420,
umls-concept:C0348013,
umls-concept:C0574032,
umls-concept:C1301732,
umls-concept:C1511253,
umls-concept:C1517927,
umls-concept:C1519043,
umls-concept:C1522449
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2001-8-2
|
|
pubmed:abstractText |
Improving the response to preoperative therapy may increase the likelihood of successful resection of locally advanced rectal cancers. Historically, the pathologic complete response (pCR) rate has been < approximately 10% with preoperative radiation therapy alone and < approximately 20% with concurrent chemotherapy and radiation therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
pubmed-author:BirnbaumE HEH,
pubmed-author:CelliniNN,
pubmed-author:CocoCC,
pubmed-author:FleshmanJ WJW,
pubmed-author:GambacortaM AMA,
pubmed-author:GenovesiDD,
pubmed-author:KodnerI JIJ,
pubmed-author:MyersonR JRJ,
pubmed-author:PicusJJ,
pubmed-author:RatkinG AGA,
pubmed-author:TuanAA,
pubmed-author:ValentiniVV
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1299-308
|
|
pubmed:dateRevised |
2009-11-3
|
|
pubmed:meshHeading |
pubmed-meshheading:11483342-Adenocarcinoma,
pubmed-meshheading:11483342-Adult,
pubmed-meshheading:11483342-Aged,
pubmed-meshheading:11483342-Aged, 80 and over,
pubmed-meshheading:11483342-Antimetabolites, Antineoplastic,
pubmed-meshheading:11483342-Colectomy,
pubmed-meshheading:11483342-Combined Modality Therapy,
pubmed-meshheading:11483342-Disease-Free Survival,
pubmed-meshheading:11483342-Female,
pubmed-meshheading:11483342-Fluorouracil,
pubmed-meshheading:11483342-Follow-Up Studies,
pubmed-meshheading:11483342-Humans,
pubmed-meshheading:11483342-Imaging, Three-Dimensional,
pubmed-meshheading:11483342-Infusions, Intravenous,
pubmed-meshheading:11483342-Intestine, Small,
pubmed-meshheading:11483342-Male,
pubmed-meshheading:11483342-Middle Aged,
pubmed-meshheading:11483342-Missouri,
pubmed-meshheading:11483342-Neoadjuvant Therapy,
pubmed-meshheading:11483342-Neoplasm Invasiveness,
pubmed-meshheading:11483342-Pelvis,
pubmed-meshheading:11483342-Proctitis,
pubmed-meshheading:11483342-Prospective Studies,
pubmed-meshheading:11483342-Radiation Injuries,
pubmed-meshheading:11483342-Radiotherapy, Adjuvant,
pubmed-meshheading:11483342-Radiotherapy, High-Energy,
pubmed-meshheading:11483342-Radiotherapy Planning, Computer-Assisted,
pubmed-meshheading:11483342-Rectal Neoplasms,
pubmed-meshheading:11483342-Remission Induction,
pubmed-meshheading:11483342-Rome,
pubmed-meshheading:11483342-Survival Analysis,
pubmed-meshheading:11483342-Treatment Outcome
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
|
|
pubmed:affiliation |
Radiation Oncology Center, Washington University School of Medicine, St. Louis MO 63110, USA. myerson@wustl.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
